ArticleCancer research2009
IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02661685 (An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- A role for pre-mNK cells in tumor progression.Journal for immunotherapy of cancer · 2016Article
- Depletion of B220Oncoimmunology · 2015Article
- Expansion of an atypical NK cell subset in mouse models of systemic lupus erythematosus.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells.Frontiers in immunology · 2013Review
- Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases.Annals of surgical oncology · 2012Article
- Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.Oncology reports · 2012Article
- Burn injury triggered dysfunction in dendritic cell response to TLR9 activation and resulted in skewed T cell functions.PloS one · 2012Article
- Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.Journal of autoimmunity · 2011Article
- Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells.Virology journal · 2011Article
- Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.Seminars in immunopathology · 2011Review
- KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-γ production.Gastroenterology · 2011Article
- Designing CD8+ T cell vaccines: it's not rocket science (yet).Current opinion in immunology · 2010Review
- Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo.Gene therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
IFN-producing killer dendritic cells (IKDC) represent a recently discovered cell type in the immune system that possesses a number of functions contributing to innate and adaptive immunity, including production of type 1 and 2 IFNs, interleukin (IL)-12, natural killing, and ultimately antigen presentation to naïve T cells. Here, we compared in vitro and in vivo responses of mouse IKDC, conventional dendritic cells (DC), and natural killer (NK) cells to murine cytomegalovirus infection and found distinct functions among these cell subsets. Upon recognition of infected fibroblasts, IKDC, as well as NK, produced high level of IFN-gamma, but unlike NK, IKDC simultaneously produced IL-12p40 and up-regulated MHC class II (MHC-II) and costimulatory molecules. Using MHC-II molecule expression as a phenotypic marker to distinguish activated IKDC from activated NK, we further showed that highly purified MHC-II(+) IKDC but not NK cross-present MHC class I-restricted antigens derived from MCMV-infected targets to CD8(+) T cells in vitro and in vivo. Our findings emphasize the unique nature of IKDC as a killer antigen-presenting cell directly linking innate and adaptive immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.